AVR: anteristech.com Market Price to Net Income Ratio

Anteris Technologies Global (AVR) business protection is based on exclusive bioprosthesis patents and strict FDA control, while the stable legal climate in the US and Australia mitigates external risks. The price action of the securities demonstrates the -5.00 indicator, illustrating the company's dynamics in heart valve development. Outstanding engineers, united by a common humanitarian goal and a drive for technological breakthrough, ensure the enterprise's success.

AVR anteristech.com: Price to Earnings Ratio in the range 12/14/2024 - 11/14/2026

Analytical breakdowns for Anteris Technologies Global

- current price and projected stock value:

Share Price Anteris Technologies Ltd|AVR - Consensus Target

- market capitalization information:

Market Value Anteris Technologies|AVR - Enterprise Value

- book capitalization indicators:

Net Asset Value per Share Anteris Technologies Global|AVR - Company Book Value|Market Value to Book Value anteristech.com|AVR - Company Total Assets

- debt and solvency information:

Total Debt to Capital Coefficient Anteris Technologies Global|AVR - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Anteris Technologies Ltd|AVR - Company Total Debt|Debt to Net Assets Ratio Anteris Technologies|AVR - Company Long-Term Liabilities|Amount of Current Liabilities Anteris Technologies Global|Immediate Liquidity anteristech.com

- business earnings and investment ratios data:

AVR - Net Profit|Future Profit Anteris Technologies Global|AVR - P/E Multiple|Future Price to Earnings Multiple Anteris Technologies Ltd|AVR - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Anteris Technologies|AVR - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Anteris Technologies Global|AVR - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months anteristech.com|AVR - Earnings per share growth in current year|Expected net earnings per share growth next year Anteris Technologies Global

- sales volume and revenue indicators:

AVR - Revenue and Sales Volume|Company Sales Forecast Anteris Technologies Ltd|AVR - P/S Multiple|Market Cap to Expected Sales Ratio Anteris Technologies

General company analysis:anteristech.com - AVR

The P/E ratio is calculated as the ratio of market capitalization to net income, determining the investment payback period. This metric measures the premium the market is willing to pay per unit of current earnings. For Anteris Technologies Global (AVR), this calculation is complicated by lengthy FDA certification cycles and patent protection for biomaterials. The price-to-earnings dynamics of the company reflect the balance between fundamental value and expectations regarding valve implementation.

Competing companies

Price to Earnings Multiple REGN (regeneron.com)|Price to Earnings Ratio IRTC (iRhythm)|Market Price to Net Income Ratio LNTH|P/E Multiple MLYS (Mineralys Therapeutics Inc)|HeartFlow (HTFL) - Market Cap to Earnings|KMTS - Price to Earnings Ratio|Company Value to Net Income ESPR (esperion.com)|AMRN: P/E Multiple|TNYA - Business Payback Period|Price to Earnings Ratio CVRx, Inc|Milestone Pharmaceuticals Inc (MIST) - Business Payback Period|Price to Earnings Ratio CRDL (Cardiol Therapeutics)|BEAT (heartbeam.com) - Company Value to Net Income|Tenax Therapeutics, Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio ADGM (Adagio Medical Holdings, Inc.)|BioCardia, Inc - P/E Multiple|Market Cap to Earnings Catheter Precision Corporation|ABIO: P/E Multiple|Price to Earnings Ratio Acasti Pharma Inc.|AVTE (Aerovate Therapeutics, Inc.) - P/E Multiple|VERV: Company Value to Net Income|Price to Earnings Ratio Windtree Therapeutics (WINT)